Risk of cardiovascular events in patients with hypercortisolism
Difficult-to-Control Type 2 Diabetes (T2D) and Hypertension May Be Masking a Bigger Threat
According to recent research, hypercortisolism may be more prevalent than previously believed.1
It may not be seen, unless you screen.
Could Hypercortisolism be driving your patients’ high blood sugar and/or blood pressure?Learn More About Recently Published Prevalence Data
In patients with difficult-to-control T2D*
Nearly 1 in 4 (24%) were identified to have endogenous hypercortisolism1
In patients with difficult-to-control T2D* and hypertension†
More than 1 in 3 (37%) were identified to have endogenous hypercortisolism1
Hypercortisolism screening is the first step
Initial screening with the 1-mg DST is inexpensive, accessible, and relatively easy to manage.3 This blood test is sensitive for all etiologies of hypercortisolism4,5
DST, dexamethasone suppression test; T2D, type 2 diabetes.
*Difficult-to-control T2D with diagnosis ≥1 year prior was defined as patients having an HbA1c of 7.5% - 11.5% and taking: ≥3 T2D medications OR insulin and other T2D medication(s) OR ≥2 T2D medications AND the presence of ≥1 microvascular or macrovascular complications AND/OR concomitant hypertension requiring ≥2 hypertension medications.4
†Patients in the CATALYST study with difficult-to-control T2D who were taking ≥3 hypertension medications.1
References
1. Buse JB, Kahn SE, Aroda VR, et al. Diabetes Care. 2025;48(00):1-9. doi:10.2337/dc24-2841 2. Petramala L, Olmati F, Concistrè A, et al. Endocrine. 2020;70(1):150-163. doi:10.1007/s12020-020-02297-2 3. Ciftel S, Mercantepe F. Cureus. 2023;15(11):e48383. doi:10.7759/cureus.48383 4. DeFronzo RA, Auchus RJ, Bancos I, et al. BMJ Open. 2024;14(7):e081121. doi:10.1136/bmjopen-2023-081121 5. Nieman LK, Biller BM, Findling JW, et al. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi:10.1210/jc.2008-0125